A Clinical Study to Evaluate the Efficacy and Safety of Habb-i Hindi (O) and Habb-i Baras (L) in the Management of Baras (Vitiligo)

Central Research Institute of Unani Medicine0 个研究点目标入组 60 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Patients of any sex in the age group between 18 and 40 Years Patients with NonSegmental Vitiligo (NSV), disease chronicity from 6 months to 2 years
•Vitiligo involving more than 2% Body Surface Area (BSA)
•Patients with less than 5 New Lesions in the last month
•Patients with less than 15 lesions in the last 3 months
•Patients who have not received systemic treatment within 4 weeks prior to study entry
•Patients who have not received topical treatment within 2 weeks prior to study entry

•Patients aged less than 18 years or more than 40 years
•Pregnant or Lactating Women
•Segmental Vitiligo (SV), liptip, or universal Vitiligo, or Vitiligo with leucotrichia
•History of Photosensitivity/Photoexaggerated Dermatoses and Connective Tissue Diseases
•Significant Pulmonary/Cardiovascular/Hepatorenal Dysfunction 6. Known cases of Immunocompromised states (HIV/ AIDS, etc.)/ Malignancies (Cutaneous or Internal)
•Patient not willing to attend treatment schedule regularly
•Patients not having a suitable facility for sun exposure

发起方